for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Karyopharm Therapeutics Inc

KPTI.N

Latest Trade

8.40USD

Change

0.25(+3.07%)

Volume

36,245

Today's Range

8.29

 - 

8.77

52 Week Range

7.80

 - 

21.54

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Karyopharm Announces Appointment Of Richard Paulson As CEO

May 3 (Reuters) - Karyopharm Therapeutics Inc <KPTI.O>::KARYOPHARM ANNOUNCES THE APPOINTMENT OF RICHARD PAULSON AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.KARYOPHARM THERAPEUTICS INC - MICHAEL G. KAUFFMAN TO REMAIN ON BOARD OF DIRECTORS AND ASSUME NEW ROLE AS SENIOR CLINICAL ADVISOR.

Karyopharm Announces European Medicines Agency's Validation Of Its Type Ii Variation Marketing Authorization Application For Nexpovio® (Selinexor) In Combination With Velcade® (Bortezomib) And D

April 26 (Reuters) - Karyopharm Therapeutics Inc <KPTI.O>::KARYOPHARM ANNOUNCES EUROPEAN MEDICINES AGENCY'S VALIDATION OF ITS TYPE II VARIATION MARKETING AUTHORIZATION APPLICATION FOR NEXPOVIO® (SELINEXOR) IN COMBINATION WITH VELCADE® (BORTEZOMIB) AND DEXAMETHASONE FOR TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS INC - EMA REGULATORY DECISION EXPECTED IN Q4 OF 2021.

Karyopharm Reports Publication of data from Phase 3 Study of Selinexor in Future Oncology

April 19 (Reuters) - Karyopharm Therapeutics Inc <KPTI.O>::KARYOPHARM ANNOUNCES PUBLICATION OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM PHASE 3 SEAL STUDY OF SELINEXOR IN ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA IN FUTURE ONCOLOGY.KARYOPHARM THERAPEUTICS INC - TREATMENT WITH SELINEXOR DEMONSTRATED SEVERAL POTENTIAL CLINICAL ADVANTAGES COMPARED TO PLACEBO.

Karyopharm Receives EC's Conditional Marketing Authorization For Nexpovio In Combination With Dexamethasone

March 29 (Reuters) - Karyopharm Therapeutics Inc <KPTI.O>::KARYOPHARM RECEIVES CONDITIONAL MARKETING AUTHORIZATION FROM THE EUROPEAN COMMISSION FOR NEXPOVIO® (SELINEXOR) IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED AND OR REFRACTORY MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS INC - SECOND EUROPEAN REGULATORY FILING BASED ON PHASE 3 BOSTON DATA EXPECTED BY APRIL 2021.

Karyopharm Therapeutics Posts Q4 Loss Per Share $0.59

Feb 11 (Reuters) - Karyopharm Therapeutics Inc <KPTI.O>::KARYOPHARM REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS.Q4 LOSS PER SHARE $0.59.Q4 EARNINGS PER SHARE ESTIMATE $-0.59 -- REFINITIV IBES DATA.NET PRODUCT REVENUE FOR Q4 OF 2020 WAS $20.2 MILLION, COMPARED TO $17.7 MILLION FOR Q4 OF 2019.Q4 REVENUE VIEW $29.4 MILLION -- REFINITIV IBES DATA.

Karyopharm Says Xpovio Receives Regulatory Approval In Israel

Feb 4 (Reuters) - Karyopharm Therapeutics Inc <KPTI.O>::KARYOPHARM ANNOUNCES XPOVIO® (SELINEXOR) RECEIVES REGULATORY APPROVAL IN ISRAEL FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA AND DIFFUSE LARGE B-CELL LYMPHOMA.KARYOPHARM - EXPECTS PROMEDICO TO RECEIVE A REGISTRATION LICENSE PROVIDING COMMERCIAL AND MARKETING AUTHORIZATION FOR XPOVIO IN ISRAEL DURING Q2.KARYOPHARM - EXPECTS TO RECEIVE A FINAL DECISION FROM EUROPEAN COMMISSION BY APRIL 2021 FOR NEXPOVIO IN COMBINATION WITH DEXAMETHASONE.

Karyopharm Receives Positive CHMP Opinion For Nexpovio® (Selinexor) For The Treatment Of Patients With Refractory Multiple Myeloma

Jan 29 (Reuters) - Karyopharm Therapeutics Inc <KPTI.O>::KARYOPHARM RECEIVES POSITIVE CHMP OPINION FOR NEXPOVIO® (SELINEXOR) FOR THE TREATMENT OF PATIENTS WITH REFRACTORY MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS INC - EUROPEAN COMMISSION DECISION ANTICIPATED BY APRIL 2021.KARYOPHARM - INTENDS TO SUBMIT SECOND REGULATORY FILING TO EMA (TYPE II VARIATION) BY APRIL 2021 ON DATA FROM CONFIRMATORY PHASE 3 BOSTON STUDY.

Karyopharm Announces Preliminary Unaudited Q4 And Full Year 2020 Total Revenues

Jan 11 (Reuters) - Karyopharm Therapeutics Inc <KPTI.O>::KARYOPHARM ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2020 TOTAL REVENUES AND PROVIDES COMMERCIAL UPDATE.SEES Q4 2020 REVENUE $35 MILLION TO $36 MILLION.SEES FY 2020 REVENUE $108 MILLION TO $109 MILLION.SEES XPOVIO (SELINEXOR) UNAUDITED NET PRODUCT SALES OF BETWEEN $20.0 MILLION AND $20.5 MILLION FOR Q4 2020.ENTRY INTO AN EXCLUSIVE DISTRIBUTION AGREEMENT FOR COMMERCIALIZATION OF XPOVIO IN CANADA WITH FORUS THERAPEUTICS INC..UNDER TERMS, RECEIVED AN UPFRONT PAYMENT OF APPROXIMATELY $5 MILLION IN DECEMBER 2020.ALSO ELIGIBLE TO RECEIVE DOUBLE-DIGIT ROYALTIES ON FUTURE NET SALES OF XPOVIO IN CANADA.Q4 REVENUE VIEW $24.9 MILLION -- REFINITIV IBES DATA.

Karyopharm Announces National Comprehensive Cancer Network Adds Three Xpovio® Treatment Regimens To Its Clinical Practice Guidelines In Oncology For Multiple Myeloma

Dec 11 (Reuters) - Karyopharm Therapeutics Inc <KPTI.O>::KARYOPHARM ANNOUNCES NATIONAL COMPREHENSIVE CANCER NETWORK® ADDS THREE XPOVIO® (SELINEXOR) TREATMENT REGIMENS TO ITS CLINICAL PRACTICE GUIDELINES IN ONCOLOGY FOR MULTIPLE MYELOMA.KARYOPHARM THERAPEUTICS - SUPPLEMENTAL NDA REQUESTING APPROVAL FOR XPOVIO HAS BEEN ASSIGNED AN FDA ACTION DATE OF MARCH 19, 2021 UNDER PDUFA.

Karyopharm Says Ongoing Phase 3 Study In Patients With Endometrial Cancer Passes Planned Interim Futility Analysis

Nov 25 (Reuters) - Karyopharm Therapeutics Inc <KPTI.O>::KARYOPHARM - ANNOUNCES ONGOING PHASE 3 SIENDO STUDY OF XPOVIO IN PATIENTS WITH ENDOMETRIAL CANCER PASSES PLANNED INTERIM FUTILITY ANALYSIS.KARYOPHARM - DATA AND SAFETY MONITORING BOARD RECOMMENDS PHASE 3 SIENDO STUDY OF XPOVIO SHOULD PROCEED AS PLANNED WITHOUT ANY MODIFICATIONS.KARYOPHARM THERAPEUTICS INC - EXPECTS TOP-LINE STUDY RESULTS IN SECOND HALF OF 2021 FOR PHASE 3 SIENDO STUDY OF XPOVIO.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up